GE launches blood collection company Drawbridge Health
GE has created Drawbridge Health, a privately held healthcare technology company focused on enabling personal diagnostic testing.
The new entity is developing proprietary technology designed to integrate blood draw, collection and sample stabilization into a single device that can be used anytime and anywhere.
GE executives say Drawbridge Health combines technology from GE Global Research, expertise from GE Healthcare and business models from GE Ventures to develop a “people-friendly system” for drawing and stabilizing blood samples.
The Drawbridge approach is being designed to offer a way for healthcare providers and diagnostic testing companies to better engage their patients and help them to manage their own health, company executives say.
As company executives see it, by introducing a simple, comfortable blood draw solution, Drawbridge Health can alter the market for patients and healthcare providers by broadening the availability and access for molecular tests for a variety of diseases, as well as provide a convenient way to monitor overall health, therapy response and disease progression.
Lee McCracken joined Drawbridge Health as CEO and a member of its board of directors.
He has more than 25 years of experience developing and growing businesses across the biotech, pharma and diagnostics sectors. Previously, he served as CEO of Gensignia Life Sciences, a molecular diagnostics company focused on the early detection of lung cancer through the integration of miRNA biology and digital health algorithms.